C O N T E N T S
TOP INTERVIEW Q A Q A Q A 10.9 22.9 66.2 ZERIA Pharmaceutical Co.,Ltd. 1
TOP INTERVIEW Q A 2 ZERIA Pharmaceutical Co.,Ltd.
ZERIA Pharmaceutical Co.,Ltd. 3 Q A Q A Q A Q A
R&D III II I II I PostPet TM C Sony Communication Network Corporation 4 ZERIA Pharmaceutical Co.,Ltd.
PREFERENTIAL TREATMENT FOR OUR SHAREHOLDERS ZERIA Pharmaceutical Co.,Ltd. 5
CONSOLIDATED FINANCIAL STATEMENTS 6 ZERIA Pharmaceutical Co.,Ltd.
ZERIA Pharmaceutical Co.,Ltd. 7
NON- CONSOLIDATED FINANCIAL STATEMENTS 8 ZERIA Pharmaceutical Co.,Ltd.
ZERIA Pharmaceutical Co.,Ltd. 9
FINANCIAL HIGHLIGHTS 10 ZERIA Pharmaceutical Co.,Ltd.
CORPORATE DATA ZERIA Pharmaceutical Co.,Ltd. 11
STOCK INFORMATION 521.37 1122.96 170.45 100.26 229,1710.47 97,5160.20 3,788 3,59794.96 18,132,084 37.55 48,290,173 12,398,44825.68 17,432,954 36.10 12 ZERIA Pharmaceutical Co.,Ltd.
SHAREHOLDER INFORMATION URL http://www.zeria.co.jp/ ZERIA Pharmaceutical Co.,Ltd. 13